Sort   by:  
 Page size 
UnknownTargeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
Not available
S-EPMC4105321 | biostudies-literature
UnknownBreast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
Not available
S-EPMC8755508 | biostudies-literature
UnknownCopy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.
Not available
S-EPMC9537519 | biostudies-literature
UnknownThe predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
Not available
S-EPMC8460445 | biostudies-literature
UnknownOvarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
Not available
S-EPMC10241792 | biostudies-literature
UnknownOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Not available
S-EPMC10207856 | biostudies-literature
UnknownGenome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.
Not available
S-EPMC6465407 | biostudies-literature
UnknownNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Not available
S-EPMC4630206 | biostudies-literature
UnknownFine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.
Not available
S-EPMC6974400 | biostudies-literature
UnknownA case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
Not available
S-EPMC7890067 | biostudies-literature
Sort   by:  
 Page size